Search clinical trials for: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1

Total 37 results

University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Recruiting

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Sun Yat-sen University
Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Active, not recruiting

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Soft Tissue Sarcoma | Bone Sarcoma

China
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Melanoma | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Neuroblastoma | Bladder Carcinoma | Synovial Sarcoma | Esophagus Carcinoma | Other Metastatic Solid Cancers

China
Guangzhou Institute of Respiratory Disease
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Unknown

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Lung Cancer, Nonsmall Cell, Recurrent

China
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)

Terminated

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Metastatic Cancer | Metastatic Melanoma

United States
Changhai Hospital

Recruiting

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Affini-T Therapeutics, Inc.

Active, not recruiting

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Other Skin

United States
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Solid Tumors

Japan
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cell Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Myxoid/Round Cell Liposarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial Sarcoma

United States
Jonsson Comprehensive Cancer Center

Active, not recruiting

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Malignant Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Liposarcoma | Adult Synovial Sarcoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Fiona Thistlethwaite
Karolinska University Hospital; University College London Hospitals; Erasmus... and other collaborators

Terminated

NY-ESO-1 T Cells in OG Cancer (ATTACK-OG)

Oesophageal Cancer

United Kingdom
M.D. Anderson Cancer Center

Completed

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Recurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid Liposarcoma

United States
CARsgen Therapeutics Co., Ltd.
Fudan University; Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Fred Hutchinson Cancer Center
Lonza Walkersville, Inc.

Recruiting

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
Roswell Park Cancer Institute
Eisai Inc.

Completed

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
Roswell Park Cancer Institute

Active, not recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
National Cancer Institute (NCI)

Not yet recruiting

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Search clinical trials for: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations